Science Daily -
8 Feb 2018 23:20
A multi-institutional phase 3 trial found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
Share this Article